Executive record
Alpha ID: alpha:person:edward-smithVersion: public-0As of: 2026-10-02
Leadership, in context.
Connect capital, control, accountability, and evidence.
Explore the record
ResponsibilitiesInspect board appointments and committee mandates.ExperienceReview career history and qualifications in context.Economic interestsExamine disclosed incentives and ownership.Key Claims
Biography
Mr. Smith has been a director since April 2020 and brings over 20 years of executive finance and operations leadership in biotechnology. He currently serves as CFO of Reunion Neuroscience, Inc. and previously served as CFO at LAVA Therapeutics, Marinus Pharmaceuticals, and PolyMedix. He held various positions in public accounting at Deloitte.
Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.
Board service
Claims
Executive career
- Dates not publishedExecutive title: Chief Financial Officer · Organization not publishedBNTC DEF 14A director slate
Claims
Compensation
Compensation coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageConflicts and accountability
Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.
Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.
Evidence, history and coverage
Additional published Claims
Published evidence records
1 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.
BNTC DEF 14A director slate
sec filing · Source published: Oct 14, 2025 · Retrieved: May 15, 2026
Supports 7 claims
- AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 15, 2026
- Board role: Board role: Director · Claim reviewed: May 15, 2026
- Committee assignments: Committee assignments: Audit, Compensation, Nominating/Governance · Claim reviewed: May 15, 2026
- Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 15, 2026
- Executive company: Executive at Reunion Neuroscience, Inc. · Claim reviewed: May 15, 2026
- Executive title: Executive title: Chief Financial Officer · Claim reviewed: May 15, 2026
- Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 15, 2026
No published record changes are available in this projection.
Identity
unclaimed
Evidence
source reported
Evaluation
Unknown
Monitoring
Unknown
Authority
Unknown
Freshness
Observed 2026-10-02
- Biography
- published
- Board service
- published
- Executive career
- published
- Education and qualifications
- not observed
- Compensation
- not observed
- Conflicts and accountability
- not observed
- Background screening
- out of scope